Introduction: Retatrutide, a Triple Hormone Receptor Agonist for Obesity
Retatrutide (LY3437943) is Eli Lilly's investigational triple hormone receptor agonist for obesity — the only late-stage compound that simultaneously activates the GLP-1, GIP, and glucagon receptors. The name researchers most often ask about — the GLP-1/GIP/glucagon triple agonist — refers to retatrutide. It is one of the most promising compounds in obesity and metabolic research, often compared to current dual-agonist treatments like tirzepatide and semaglutide.
Recent Phase 3 results from the TRIUMPH program show triple agonist weight loss outcomes that approach those seen with bariatric surgery.
How the Retatrutide Triple Hormone Receptor Agonist Works
Retatrutide is classified as a triple hormone receptor agonist because it activates three complementary metabolic pathways in a single molecule:
- GLP-1 receptor activation — slows gastric emptying, reduces appetite, and improves insulin secretion.
- GIP receptor activation — enhances insulin response and supports fat metabolism.
- Glucagon receptor activation — increases energy expenditure and fat breakdown.
This triple action is what separates retatrutide from single-agonist (semaglutide) and dual-agonist (tirzepatide) compounds — hunger is suppressed while resting metabolism is raised, which may explain why triple agonist weight loss continues without the early plateaus seen with single- or dual-receptor approaches.
Key Clinical Trial Results
TRIUMPH-1 Phase 3 Trial (Obesity without Diabetes)
In this large study with over 2,300 participants:
- 12 mg dose: Average 28.3% body weight loss (70.3 lbs / 31.9 kg) at 80 weeks.
- 9 mg dose: Average 25.9% weight loss (64.4 lbs).
- 4 mg dose: Average 19.0% weight loss (47.2 lbs).
- Placebo: Only 2.2% weight loss.
Notably, 45.3% of participants on the 12 mg dose achieved 30% or greater weight loss. At 104 weeks in an extension, those continuing 12 mg reached an average of 30.3% weight loss (85 lbs).
TRIUMPH-4 Phase 3 Trial (Obesity with Knee Osteoarthritis)
Participants on 12 mg lost an average of 28.7% body weight (71.2 lbs) at 68 weeks, along with significant reductions in knee pain.
Additional Benefits Observed Across Trials
- Reduced waist circumference
- Improvements in triglycerides, non-HDL cholesterol, blood pressure, and inflammation markers (hsCRP)
- Better blood sugar control in diabetes-related studies
Retatrutide vs Tirzepatide and Semaglutide
Retatrutide's added glucagon activity appears to drive greater triple agonist weight loss and continued progress compared to dual-agonist tirzepatide and single-agonist semaglutide. Researchers are actively comparing these compounds to understand the benefits of triple receptor activation for obesity. See our detailed comparisons: Retatrutide vs Semaglutide and Retatrutide vs Tirzepatide.
Researchers asking where to buy retatrutide for in-vitro work should compare HPLC purity, batch-specific third-party COAs, and USA dispatch times before price — our best place to buy retatrutide online guide covers the 10mg, 30mg and 50mg options, reconstitution reference tables, and cost per mg.
Retatrutide Research Dosage Protocols
Important: The following are summaries from published clinical trials and are for laboratory research use only.
- Standard Research Dosing: Starts low (e.g., 2 mg) with gradual escalation every 4 weeks up to 4 mg, 9 mg, or 12 mg once weekly.
- Common Maintenance: 9–12 mg once weekly in longer-term studies.
- Administration: Subcutaneous injection.
- Cycle Length: Most Phase 3 trials run 68–104 weeks with ongoing monitoring.
Reconstitution Note (Research Only): Use bacteriostatic water and follow standard peptide handling procedures.
Why Researchers Are Excited About Retatrutide
Retatrutide stands out for delivering bariatric-level weight loss (25–30%+) through pharmacological means, along with strong improvements in cardiometabolic health. Its ability to reduce liver fat, support joint health, and maintain weight loss momentum makes it a leading compound in metabolic research.
Important Research Notice: Retatrutide is an investigational compound sold by Amino Fuel Labs strictly for laboratory research and in vitro use only. It is not FDA-approved for human consumption.
For research professionals studying obesity, metabolic disorders, or next-generation weight loss peptides, we provide high-purity Retatrutide with independent testing and fast domestic shipping.
Browse our full selection of research peptides including Tirzepatide, AOD9604, 5-Amino-1MQ, MOTS-c, and more.
Have questions about Retatrutide research protocols, stacking ideas, or comparing trial results? Leave a comment below — we're here to support the research community.
Frequently Asked Questions
What is the name of the GLP-1/GIP/glucagon triple agonist?
The leading GLP-1/GIP/glucagon triple agonist in clinical development is retatrutide (development code LY3437943), an Eli Lilly investigational peptide. It is the first triple hormone receptor agonist to reach Phase 3 obesity trials.
Is retatrutide a triple hormone receptor agonist for obesity?
Yes. Retatrutide is the only triple hormone receptor agonist for obesity currently in late-stage trials, activating GLP-1, GIP, and glucagon receptors in one molecule. Phase 3 TRIUMPH data show up to 28.3% body weight loss at 80 weeks on the 12 mg dose.
How much triple agonist weight loss does retatrutide produce?
In Phase 3 TRIUMPH-1, the 12 mg dose produced an average of 28.3% body weight loss at 80 weeks, with 45.3% of participants losing 30% or more. At 104 weeks, those continuing on 12 mg reached an average of 30.3% weight loss — the highest reported for any pharmacological obesity therapy to date.
How is retatrutide different from tirzepatide?
Tirzepatide is a dual GLP-1/GIP agonist; retatrutide adds a third pathway — glucagon receptor activation — which increases energy expenditure on top of appetite suppression. That third mechanism is what drives the larger weight loss observed in head-to-head trial comparisons.
